Novel Approaches to Diseases of Unknown Etiology¶
Chapter 505 | Part 20: Emerging Topics in Clinical Medicine
KEY CLINICAL POINTS¶
- Undiagnosed diseases are rare, chronic conditions with complex etiologies, often requiring multidisciplinary approaches for diagnosis.
- Genomic sequencing (exome/genome) and agnostic testing are critical tools for identifying novel disease-gene associations.
- Periodic reevaluation and collaboration with research networks (e.g., UDN) improve diagnostic yield and patient outcomes.
- Environmental and genetic factors, including exposome analysis, play a significant role in disease pathogenesis.
- Comprehensive data collection, including longitudinal records and family history, is essential for accurate diagnosis.
1. DEFINITION & OVERVIEW¶
An undiagnosed disease refers to a condition for which a medical diagnosis cannot be established after reasonable efforts using established methods. The term encompasses both rare and common disorders with atypical presentations, misleading test results, or incomplete clinical data. The undiagnosed state poses challenges for patients, families, and providers due to uncertainty, lack of targeted therapies, and potential for prolonged suffering.
Table 505-1: Factors Contributing to the Presence of an Undiagnosed Disease¶
| FACTOR | EXAMPLE |
|---|---|
| Misleading information | False-negative and false-positive test results |
| Rare disorder | Sialuria (OMIM 269921) |
| Unusual causes of common diseases | Insulin-dependent diabetes mellitus as presenting feature of autoimmune polyendocrinopathy syndrome |
| Presence of multiple disorders | See PubMed ID 24863970 |
| Lack of characteristic symptoms | Marfan’s syndrome without tall stature |
| Diseases not expected in region/population | Cystic fibrosis in African ancestry, sickle cell disease in northern European ancestry |
| Diseases thought to be eradicated | Poliomyelitis |
| Diseases occurring in unexpected time of life | Parkinson’s disease in children, lysosomal storage disease in adults |
| FACTOR | EXAMPLE |
|---|---|
| Malingering | Feigned disease features for secondary gain (Munchausen syndrome) |
| Rare disease mechanisms | Transmitted or sporadic prion disease, unusual zoonotic diseases |
1.1 The Undiagnosed Disease State¶
Defined as a condition where no prior knowledge or record of the disease exists. Factors contributing to undiagnosed states include misleading test results, rare disease mechanisms, incorrect family history, and atypical disease presentations. Patients may remain undiagnosed for decades, leading to significant personal and societal impacts.
1.2 Diagnostic Hierarchy¶
Diagnoses are hierarchical, ranging from clinical (e.g., Parkinson’s disease) to molecular (e.g., mutations in SYNCA gene) and histopathologic (e.g., Lewy body pathology). Precision medicine emphasizes integrating genomic, environmental, and social factors to refine diagnostic approaches.
2. EPIDEMIOLOGY¶
Approximately 6,000 rare diseases affect millions globally, with prevalence estimates of 6–10%. Many are genetic, with onset in childhood. Undiagnosed diseases are often rare, with individual disorders having low prevalence but collectively comprising a significant burden. Environmental and genetic factors, including exposome analysis, contribute to disease risk.
Table 505-2: Essential Records for Undiagnosed Disease Patients¶
| Record Type |
|---|
| Narrative summaries of illness course |
| Original test results (names, dates, normal ranges) |
| Electronic imaging studies |
| Consultation notes and karyotype |
| Hospitalization summaries |
| Accurate family history |
2.1 Demographics¶
Rare diseases often have genetic bases and childhood onset. Environmental exposures (e.g., toxins, occupational hazards) may interact with genetic susceptibility. Undiagnosed diseases may disproportionately affect certain populations due to geographic or genetic factors (e.g., sickle cell disease in African ancestry).
3. ETIOLOGY & PATHOPHYSIOLOGY¶
Undiagnosed diseases may arise from genetic mutations, environmental exposures, or complex interactions between the two. Rare genetic disorders (e.g., lysosomal storage diseases) often present with atypical or nonspecific symptoms. Environmental factors, including chemical toxins and occupational hazards, may contribute to disease pathogenesis through mechanisms such as epigenetic modulation or metabolic disruption.
Table 505-3: Clinically Available Tests for Undiagnosed Cases¶
| TEST | TARGET PHENOTYPES | RATIONALE |
|---|---|---|
| Single nucleotide polymorphism microarray/karyotype | Dysmorphic features, cognitive impairment, neurodevelopmental disorders | Genomic abnormalities missed by other testing |
| Lysosomal storage diseases (LSDs) | Progressive neurologic disorders, psychiatric disorders | Nonspecific presentations, adult-onset cases often missed |
| Biochemical disorders (ammonia, amino acids, fatty acids) | Neurologic phenotypes with waxing/waning course | Metabolic disorders with nonspecific symptoms |
| Cerebrospinal fluid (CSF) studies | Synthetic neurotransmitter defects, neuroinflammatory syndromes | Patterns of profiles point to enzymatic deficits |
3.1 Genetic Basis¶
Many rare diseases have monogenic inheritance (e.g., sialuria, OMIM 269921). Genomic sequencing and exome-wide analyses are critical for identifying novel disease-gene associations. Mutations in genes like SYNCA (alpha-synuclein) are linked to neurodegenerative disorders.
3.2 Environmental Contributions¶
Exposome analysis captures the totality of environmental exposures (chemical, dietary, microbiome) over a lifetime. Toxicants like manganese or halogenated hydrocarbons may interact with genetic susceptibility to produce atypical disease presentations (e.g., manganese-induced parkinsonism).
4. CLINICAL FEATURES¶
Clinical presentations of undiagnosed diseases are often nonspecific, atypical, or inconsistent with known diagnoses. Symptoms may wax and wane, and patients may exhibit adaptive or maladaptive coping strategies. Complications include prolonged suffering, decreased quality of life, and increased healthcare utilization.
4.1 Symptomatology¶
Patients may present with fluctuating symptoms (e.g., waxing/waning neurologic deficits), psychiatric manifestations, or metabolic abnormalities. Atypical presentations of well-characterized diseases (e.g., manganese-induced parkinsonism) may initially be mistaken for undiagnosed conditions.
4.2 Complications¶
Prolonged undiagnosed states lead to personal and familial stress, limited access to targeted therapies, and increased healthcare costs. Patients may experience significant psychological distress and social isolation.
5. DIFFERENTIAL DIAGNOSIS¶
Differential diagnosis includes rare genetic disorders, environmental exposures, and psychiatric conditions (e.g., functional syndromes). Misdiagnosis may occur due to misleading test results, incomplete family history, or atypical disease progression. Consideration of rare diseases with overlapping phenotypes (e.g., autoimmune polyendocrinopathy syndrome) is critical.
5.1 Functional Syndromes¶
Patients with 'functional' or 'somatoform' disorders may have underlying organic pathology (e.g., nonepileptic events mistaken for seizures). Careful clinical and laboratory evaluation is required to distinguish these from true organic diseases.
6. INVESTIGATIONS & DIAGNOSIS¶
Diagnostic approaches include genomic sequencing (exome/genome), metabolomics, epigenetic analysis, and environmental exposure assessment. Agnostic testing (e.g., whole-genome sequencing) is preferred when no specific hypothesis exists. Periodic reevaluation and collaboration with research networks (e.g., UDN) improve diagnostic yield.
Table 505-4: Emerging Testing Strategies and Diagnostic Questions¶
| TESTING STRATEGY | RELATED DIAGNOSTIC QUESTION | CLINICALLY AVAILABLE |
|---|---|---|
| Transcriptomics/RNA-Seq | Relevance of splice variants, gene expression changes | Yes |
| Epigenetics | Diseases caused by methylation or parent-of-origin effects | Yes |
| Metagenomics | Search for infectious agents in human samples | Yes |
| Deep sequencing | Accurate resolution of low-level mosaicism | Some |
| Long-read sequencing | Resolution of complex genome structural rearrangements | No |
6.1 Molecular Testing¶
Hypothesis-driven testing uses targeted gene panels, while agnostic testing (e.g., exome sequencing) explores all possible genetic variants. Genomic reanalysis of previously obtained data may yield new insights with advances in bioinformatics.
6.2 Environmental Assessment¶
Detailed occupational and environmental history is critical. Toxicant exposures (e.g., asbestos, DES) may produce pathognomonic findings, while others (e.g., volatile organics) require correlation with clinical symptoms.
7. MANAGEMENT & TREATMENT¶
Management focuses on symptomatic care, support for the undiagnosed state, and periodic reevaluation. Therapies may include targeted interventions for identified genetic or environmental causes. Collaboration with research networks and patient advocacy groups is essential for long-term care.
7.1 Symptomatic Care¶
Empiric treatments may be used to manage symptoms while awaiting a definitive diagnosis. Supportive care addresses psychological and social impacts of prolonged uncertainty.
7.2 Research Collaboration¶
Engagement with research networks (e.g., UDN) and patient advocacy groups (e.g., NORD) improves diagnostic outcomes. Data sharing and phenotypic matching via platforms like GeneMatcher enhance collaborative efforts.
8. PROGNOSIS & COMPLICATIONS¶
Prognosis varies widely depending on the underlying cause. Complications include prolonged suffering, psychological distress, and increased healthcare utilization. Early diagnosis and targeted therapies improve outcomes, while undiagnosed states may lead to progressive disability or mortality.
8.1 Long-Term Outcomes¶
Chronic undiagnosed diseases may progress over decades, with complications arising from both the disease itself and the stress of uncertainty. Periodic reevaluation and adaptive management strategies are critical.
9. SPECIAL CONSIDERATIONS¶
Special considerations include the impact of undiagnosed diseases on pregnancy, pediatric populations, and elderly patients. Environmental exposures and genetic factors may interact differently across age groups, requiring tailored diagnostic and management approaches.
9.1 Pediatric and Geriatric Populations¶
Pediatric-onset disorders (e.g., lysosomal storage diseases) may present with atypical features. Geriatric patients may exhibit complex interactions between genetic and environmental factors, complicating diagnosis.
10. KEY POINTS & CLINICAL PEARLS¶
- Undiagnosed diseases require multidisciplinary, iterative diagnostic approaches. 2. Genomic sequencing and agnostic testing are essential for identifying novel disease-gene associations. 3. Periodic reevaluation and collaboration with research networks (e.g., UDN) improve diagnostic yield. 4. Environmental and genetic factors, including exposome analysis, play critical roles in disease pathogenesis. 5. Comprehensive data collection and patient engagement are vital for accurate diagnosis and long-term management.